Ustekinumab biosimilar - Oncobiologics

Drug Profile

Ustekinumab biosimilar - Oncobiologics

Alternative Names: ONS-3040

Latest Information Update: 22 Oct 2015

Price : $50

At a glance

  • Originator Oncobiologics
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Psoriasis

Most Recent Events

  • 22 Oct 2015 Preclinical trials in Psoriasis in USA (SC) prior to October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top